Canada markets close in 16 minutes

NVS Jan 2026 60.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
48.000.00 (0.00%)
As of 04:35PM EDT. Market open.
Full screen
Previous Close48.00
Open48.00
Bid39.00
Ask44.00
Strike60.00
Expire Date2026-01-16
Day's Range48.00 - 48.00
Contract RangeN/A
Volume1
Open InterestN/A
  • Thomson Reuters StreetEvents

    Q1 2024 Legend Biotech Corp Earnings Call

    Q1 2024 Legend Biotech Corp Earnings Call

  • GlobeNewswire

    Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

    – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for

  • The Telegraph

    Questor: this medical stock is expensive – but worth paying for

    It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.